Loading...
•
Sep 30, 2022
Voyager Therapeutics Q3 2022 Earnings Report
Voyager Therapeutics reported financial results for the third quarter of 2022, marked by Pfizer's license of a novel TRACER capsid and advancements in pipeline programs.
Key Takeaways
Voyager Therapeutics reported a net income of $17.6 million for Q3 2022, a significant increase compared to a net loss of $25.1 million for the same period in 2021. This was primarily driven by a substantial increase in collaboration revenue, particularly from Pfizer's option exercise to license a novel capsid from Voyager's TRACER platform.
Pfizer exercised its option to license a novel TRACER capsid for a rare neurologic disease target.
Data presented at ESGCT characterized a novel CNS receptor and demonstrated low-dose potential of TRACER capsids.
Pipeline programs for Alzheimer’s disease, Parkinson’s disease and ALS are progressing with development candidate selections expected soon.
Voyager's cash, cash equivalents, and marketable securities were $131.6 million as of September 30, 2022, which doesn't include the $10 million option exercise payment received in October 2022.
Voyager Therapeutics
Voyager Therapeutics
Voyager Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Voyager expects its current cash reserves and anticipated reimbursements to fund operations into 2024, with potential for further runway extension based on milestone achievements in 2023.
Positive Outlook
- Cash runway extends into 2024.
- Potential for additional milestones in 2023.
- Advancing pipeline programs for Parkinson’s, Alzheimer’s and ALS.
- Novartis option decision expected by March 2023.
- Voyager plans to identify lead development candidates for all three programs between Q4 2022 and H1 2023
Challenges Ahead
- Forward-looking statements are subject to risks and uncertainties.
- Reliance on continued development of technology platforms.
- Dependence on third-party collaborations.
- Uncertainty in preclinical study outcomes.
- Risk of competitive capsid identification platforms.